Enzychem Lifesciences Completes Stage 1 Patient Enrollment in Phase 2 CRIOM Study
Enzychem Lifesciences, Corp. announced that the company has achieved a huge milestone by completing enrollment of the required 24 patients in Stage 1 of the Phase 2 CRIOM (Chemoradiation Induced Oral Mucositis) study.
Stage 1 of the Phase 2 CRIOM study evaluates the maximum tolerable dose of EC-18 which will be used in Stage 2 of the study. Patient enrollment for Stage 2 is expected to begin in 2Q 2019. Enzychem has received Fast Track Designation by the U.S. Food and Drug Administration for the Phase 2 study evaluating lead investigational candidate EC-18 in CRIOM.
Enzychem Lifesciences, Corp. (KOSDAQ:183490) is a global biopharmaceutical company headquartered in Seoul, Korea, which is dedicated to developing new drugs and APIs (Active Pharmaceutical Ingredients). Since its foundation in 1999, Enzychem Lifesciences has been striving to develop new and innovative treatments capable of addressing unmet medical needs with R&D-driven approaches under its grand mission of "Saving Human Lives by Overcoming Unmet Medical Needs"
Read more: https://prn.to/2IFlcuC
Stage 1 of the Phase 2 CRIOM study evaluates the maximum tolerable dose of EC-18 which will be used in Stage 2 of the study. Patient enrollment for Stage 2 is expected to begin in 2Q 2019. Enzychem has received Fast Track Designation by the U.S. Food and Drug Administration for the Phase 2 study evaluating lead investigational candidate EC-18 in CRIOM.
Enzychem Lifesciences, Corp. (KOSDAQ:183490) is a global biopharmaceutical company headquartered in Seoul, Korea, which is dedicated to developing new drugs and APIs (Active Pharmaceutical Ingredients). Since its foundation in 1999, Enzychem Lifesciences has been striving to develop new and innovative treatments capable of addressing unmet medical needs with R&D-driven approaches under its grand mission of "Saving Human Lives by Overcoming Unmet Medical Needs"
Read more: https://prn.to/2IFlcuC
